Gastroparesis disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GST037 MIFTS: 54	Gastroparesis Categories: Gastrointestinal diseases, Metabolic diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Name: Gastroparesis ¹² ⁵² ⁵⁴ ⁴³ ¹⁵ ¹⁷ ⁷¹

Delayed Gastric Emptying ⁵²

Gastroparesis Syndrome ¹²

Gastroparalysis ¹²

Gastric Atonia ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Metabolic diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:11914

ICD9CM ³⁴ 536.3

MeSH ⁴³ D018589

NCIt ⁴⁹ C80512

SNOMED-CT ⁶⁷ 196753007

ICD10 ³² K31.84

EFO ¹⁷ EFO_1000948

UMLS ⁷¹ C0152020

Sources

Summaries for Gastroparesis

NIH Rare Diseases : ⁵² Gastroparesis , or delayed gastric emptying, is a disorder where the food does not move or moves very slowly from the stomach to the small intestine . In gastroparesis, the muscles of the stomach do not work well and digestion takes an abnormally long time. Symptoms of gastroparesis include bloating, nausea, vomiting, weight loss due to poor absorption of nutrients, early fullness while eating meals, heartburn, and abdominal pain. Complications can occur including dehydration, electrolyte abnormalities, blood sugar abnormalities, malnutrition, vitamin deficiencies, stomach ulcers , gastroesophageal reflux , esophagitis , small bowel bacterial overgrowth , and metabolic bone disease. In rare cases, food that is poorly digested can collect in the stomach and form a bezoar, a mass of undigested material that can cause a blockage in the gastrointestinal tract. Gastroparesis is more common in people with diabetes and those who have had recent stomach or intestinal surgery. Other causes include infections, hormonal disorders like hypothyroidism, connective tissue disorders like scleroderma , autoimmune conditions , neuromuscular diseases , psychological conditions, and eating disorders. In some cases, the cause is not known (idiopathic). Diagnosis is made on the basis of a radiographic gastric emptying test . Treatment may include dietary modifications such as adjusting the timing and size of meals, consuming more liquid-based meals, or avoiding foods that are more difficult to digest (such as fatty foods, or foods with too much fiber). Other treatments may include endoscopic procedures to break the bezoar apart and remove it, feeding tubes, surgery, placement of an electrical stimulator , and medication such as metoclopramide , domperidone, erythromycin and cisapride . With proper management many people with gastroparesis can live a relatively normal life. However, others may not tolerate treatment and may experience significant complications, a decreased quality of life, and reduced survival.

MalaCards based summary : Gastroparesis, also known as delayed gastric emptying, is related to idiopathic gastroparesis and stomach disease, and has symptoms including ophthalmoplegia, hemiplegia and signs and symptoms, digestive. An important gene associated with Gastroparesis is MLN (Motilin), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Glucagon and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include testes, small intestine and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : ⁷⁴ Gastroparesis (gastro- from Ancient Greek γαστήρ - gaster, "stomach"; and -paresis, πάρεσις - "partial... more...

Sources

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)

#	Related Disease	Score	Top Affiliating Genes
1	idiopathic gastroparesis	32.1	MRC1 HMOX1 GIP GHSR GHRL
2	stomach disease	32.0	SST MLNR MLN GHRL GAST CCK
3	autonomic neuropathy	31.2	MLNR MLN GAST CCK
4	diabetic autonomic neuropathy	31.0	MLNR MLN GAST
5	pylorospasm	31.0	MLNR MLN
6	tardive dyskinesia	30.9	DRD3 DRD2 CYP2D6
7	gastroesophageal reflux	30.6	MLN GHRL GAST DRD2 CCK
8	rumination disorder	30.5	MLNR HTR3A
9	pyloric stenosis	30.5	SST NOS1 MLN GAST
10	peptic ulcer disease	30.5	SST GHRL GAST
11	small cell cancer of the lung	30.2	SST GAST CCK
12	atrophic gastritis	30.2	SST GHRL GAST
13	duodenal ulcer	30.1	SST MLN GAST CCK
14	eating disorder	30.1	GHRL DRD3 DRD2 CCK
15	gastrointestinal system disease	30.1	MLN GHRL GAST CCK
16	cholelithiasis	30.0	SST GAST CCK
17	mucositis	30.0	HTR3A GHRL ABCB1
18	duodenogastric reflux	29.9	SST MLN GAST CCK
19	gallbladder disease	29.9	SST MLN CCK
20	intestinal obstruction	29.9	SST MLNR MLN GHRL ANO1
21	tetrahydrobiopterin deficiency	29.9	TH NOS1
22	irritable bowel syndrome	29.8	SST MLN HTR3A GHRL CCK
23	pain agnosia	29.8	HTR3A CYP2D6 CCK
24	ileus	29.7	SST MLN GHSR GHRL CCK
25	biliary dyskinesia	29.7	SST CCK
26	bulimia nervosa	29.7	HTR3A GHRL DRD2 CCK
27	hyperglycemia	29.5	SST GIP GHRL CCK
28	sexual disorder	29.4	NOS1 HTR3A DRD3 DRD2 CYP3A4 CYP2D6
29	diarrhea	29.3	SST MLN HTR3A GAST CYP3A4 CYP2D6
30	mood disorder	29.2	TH NOS1 HTR3A DRD3 DRD2 DRD1
31	dumping syndrome	29.0	SST MLN GIP GHRL GAST CCK
32	anxiety	28.9	TH HTR3A DRD3 DRD2 CYP3A4 CYP2D6
33	migraine with or without aura 1	28.9	NOS1 HTR3A DRD3 DRD2 DRD1 CYP3A4
34	alcohol dependence	28.9	TH HTR3A GHRL DRD3 DRD2 DRD1
35	diabetes mellitus	28.5	TH SST MLN HMOX1 GIP GHRL
36	constipation	28.4	TH SST NOS1 MLNR MLN HTR3A
37	parkinson disease, late-onset	28.4	TH NOS1 HTR3A HMOX1 DRD3 DRD2
38	diabetes mellitus, noninsulin-dependent	27.7	TH SST HMOX1 GIP GHRL DRD2
39	brittle diabetes	11.6
40	galactorrhea	10.6	DRD2 CYP2D6
41	gastrointestinal neuroendocrine benign tumor	10.5	SST GAST
42	non-functioning pancreatic endocrine tumor	10.5	SST GAST
43	rectum neuroendocrine neoplasm	10.5	SST GAST
44	hypertrophy of tongue papillae	10.5	CYP3A4 CYP2D6
45	early-onset schizophrenia	10.5	DRD2 DRD1
46	gastric neuroendocrine neoplasm	10.5	SST GAST
47	polysubstance abuse	10.5	DRD3 DRD2
48	duodenal gastrinoma	10.5	SST GAST
49	appendix lymphoma	10.5	SST GAST
50	glucagonoma	10.5	SST GAST

Graphical network of the top 20 diseases related to Gastroparesis:

Sources

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:

ophthalmoplegia, hemiplegia, signs and symptoms, digestive, lassitude, persistent vomiting

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00240-S-1	9.89	SST
2	Decreased viability	GR00249-S	9.89	ABCB1 ANO1 GHRL GHSR MLN NOS1
3	Decreased viability	GR00381-A-1	9.89	CYP2D6 GHSR HTR3A MLN MLNR
4	Decreased viability	GR00381-A-2	9.89	GHSR
5	Decreased viability	GR00381-A-3	9.89	GHSR HTR3A MLN
6	Decreased viability	GR00386-A-1	9.89	CCK DRD1 MLN
7	Decreased viability	GR00402-S-2	9.89	ABCB1 CYP2D6 GHSR HTR3A MLN

MGI Mouse Phenotypes related to Gastroparesis:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	10.18	ABCB1 ANO1 DRD1 DRD2 DRD3 GHRL
2	digestive/alimentary	MP:0005381	10.11	ABCB1 ANO1 DRD1 DRD2 DRD3 GAST
3	homeostasis/metabolism	MP:0005376	10.06	ABCB1 ANO1 CCK DRD1 DRD2 DRD3
4	growth/size/body region	MP:0005378	10.03	ABCB1 ANO1 DRD1 DRD2 DRD3 GHSR
5	adipose tissue	MP:0005375	9.98	DRD1 DRD2 DRD3 GHRL GHSR HMOX1
6	endocrine/exocrine gland	MP:0005379	9.97	ABCB1 CCK DRD2 GAST GHRL HMOX1
7	no phenotypic analysis	MP:0003012	9.5	ABCB1 CCK DRD2 GHSR NOS1 SST
8	renal/urinary system	MP:0005367	9.17	ANO1 CCK DRD2 DRD3 HMOX1 HTR3A

Sources

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 219)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Glucagon

Approved

Phase 4

16941-32-5

Levodopa

Approved

Phase 4

59-92-7

6047

Bismuth subsalicylate

Approved, Vet_approved

Phase 4

14882-18-9

53629521

Omeprazole

Approved, Investigational, Vet_approved

Phase 4

73590-58-6

4594

Esomeprazole

Approved, Investigational

Phase 4

161796-78-7, 119141-88-7, 161973-10-0

9568614 4594

Carbidopa

Approved

Phase 4

28860-95-9

34359

Trimethobenzamide

Approved, Investigational

Phase 4

138-56-7

5577

Apomorphine

Approved, Investigational

Phase 4

41372-20-7, 58-00-4

6005

Linaclotide

Approved

Phase 4

851199-59-2

65351

Ticagrelor

Approved

Phase 4

274693-27-5

9871419

Cangrelor

Approved

Phase 4

163706-06-7

9854012

Acetylcholine

Approved, Investigational

Phase 4

51-84-3

187

Dopamine

Approved

Phase 4

51-61-6, 62-31-7

681

Haloperidol

Approved

Phase 4

52-86-8

3559

Vitamin C

Approved, Nutraceutical

Phase 4

50-81-7

5785 54670067

Mosapride

Investigational

Phase 4

112885-41-3

Pharmaceutical Solutions

Phase 4

Dihydroxyphenylalanine

Phase 4

Proton Pump Inhibitors

Phase 4

Dopamine agonists

Phase 4

Emetics

Phase 4

Antiparkinson Agents

Phase 4

Adjuvants, Immunologic

Phase 4

Carbidopa, levodopa drug combination

Phase 4

Aromatic Amino Acid Decarboxylase Inhibitors

Phase 4

Laxatives

Phase 4

Cathartics

Phase 4

Polyethylene glycol 3350

Phase 4

Purinergic P2Y Receptor Antagonists

Phase 4

Platelet Aggregation Inhibitors

Phase 4

abobotulinumtoxinA

Phase 4

Cholinergic Agents

Phase 4

Botulinum Toxins, Type A

Phase 4

Botulinum Toxins

Phase 4

Dopamine Agents

Phase 4

Dopamine Antagonists

Phase 4

Antiemetics

Phase 4

Gastrointestinal Agents

Phase 4

Neurotransmitter Agents

Phase 4

Antacids

Phase 4

Anti-Ulcer Agents

Phase 4

Serotonin Receptor Agonists

Phase 4

Psychotropic Drugs

Phase 4

Antipsychotic Agents

Phase 4

Opiate Alkaloids

Phase 4

Haloperidol decanoate

Phase 4

Serotonin

Investigational, Nutraceutical

Phase 4

50-67-9

5202

Granisetron

Approved, Investigational

Phase 3

109889-09-0

3510

Prucalopride

Approved

Phase 2, Phase 3

179474-81-8

Erythromycin

Approved, Investigational, Vet_approved

Phase 2, Phase 3

114-07-8

12560 441411

Interventional clinical trials:

(show top 50) (show all 349)

#	Name	Status	NCT ID	Phase	Drugs
1	Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying	Unknown status	NCT02510976	Phase 4	prucalopride;placebo
2	Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.	Unknown status	NCT02251249	Phase 4	Paracetamol concentration time curve from 0 to 120 min
3	Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2	Unknown status	NCT00473733	Phase 4
4	Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis	Unknown status	NCT02264587	Phase 4	Mosapride;domperidone
5	Pharmacokinetics of Immediate-Release vs. Delayed-Release Omeprazole in Patients With Heartburn Associated With Gastroparesis	Completed	NCT00492622	Phase 4	Immediate-release omeprazole;Delayed-release omeprazole
6	Effect of Proton Pump Inhibitor on Gastric Emptying and Satiety Function in Patients With Functional Dyspepsia	Completed	NCT00951431	Phase 4	Esomeprazole;Placebo
7	A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action	Completed	NCT01770145	Phase 4	APOKYN;L-dopa;Trimethobenzamide
8	Reduction of Postoperative Gastrointestinal Dysmotility Following Total Laparoscopic Hysterectomy: a Randomized Control Trial.	Completed	NCT03800745	Phase 4	Colace 100Mg Capsule;Miralax
9	Single-dose Linaclotide for Capsule Endoscopy Preparation	Completed	NCT02465385	Phase 4	Linaclotide
10	A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding	Completed	NCT01654770	Phase 4
11	PEG-Electrolyte Solution (FORTRANS®) With Mentholyptus Drops (Halls®) Versus Reduced Volume Ascorbic Acid Supplemented PEG-Electrolyte (MoviPrep®) in Colonoscopy Preparation: A Randomised Controlled Study	Completed	NCT01788709	Phase 4
12	Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial	Recruiting	NCT01642875	Phase 4
13	Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit	Recruiting	NCT04210427	Phase 4	Polyethylene Glycol 3350
14	Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention	Recruiting	NCT04005729	Phase 4	Cangrelor 50 MG
15	Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy	Enrolling by invitation	NCT03701919	Phase 4	Botulinum toxin pyloroplasty;Normal saline pyloric injection
16	Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of R051619 (Cisapride 10 mg Q.I.D.) Versus Placebo for the Improvement of Symptoms Associated With Exacerbations of Gastroparesis, After Failure of Other Treatments, in Patients With Diabetes Mellitus	Terminated	NCT01286090	Phase 4	Cisapride;Placebo
17	An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms	Terminated	NCT00390975	Phase 4	Tegaserod
18	Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options	Terminated	NCT01281540	Phase 4	Cisapride;Placebo
19	Enterra Therapy Gastric Stimulation System	Terminated	NCT00556166	Phase 4
20	Haloperidol vs Conventional Therapy for Gastroparesis	Terminated	NCT02057549	Phase 4	Haloperidol;Conventional Therapy
21	Daily Tadalafil and Gastric Emptying Time in Diabetic Gastroparesis	Withdrawn	NCT01326117	Phase 4	tadalafil
22	Prospective Randomized Double-blind Study of Incisional Local Anesthesia in Laparoscopic Surgery (Ketorolac Versus Normal Saline)	Withdrawn	NCT01374828	Phase 4	Ketolorac
23	A Randomized Controlled Trial of Gastric Meal With and Without Prior Jejunal Feeding on GI Symptoms and Response in Patients With Diabetic Gastro-enteropathy, Diabetic Controls and Healthy Volunteers	Withdrawn	NCT00944593	Phase 4
24	Comparison Between Antecolic and Retrocolic Gastrointestinal Reconstruction in Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective Randomized Controlled Multicenter Trial	Unknown status	NCT01460550	Phase 3
25	Role of Routine Nasogastric Decompression After Subtotal Gastrectomy	Unknown status	NCT00164918	Phase 3
26	Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study.	Unknown status	NCT01989221	Phase 3	Sancuso®
27	Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy	Unknown status	NCT02927886	Phase 3
28	Effect of Electroacupuncture in Diabetic Patients With Gastroparesis	Unknown status	NCT00227383	Phase 3
29	Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis	Completed	NCT02025751	Phase 3	Metoclopramide Nasal Spray;Placebo Nasal Spray
30	Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis	Completed	NCT02025725	Phase 3	Metoclopramide Nasal Spray;Placebo Nasal Spray
31	Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis	Completed	NCT00432835	Phase 3
32	Phase III Study for the Significance of Nasogastric Decompression Tube After Curative Distal Gastrectomy for Gastric Cancer Patients	Completed	NCT00738478	Phase 3
33	Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)	Completed	NCT00765895	Phase 3	Nortriptyline Hydrochloride;Placebo (for nortriptyline)
34	Sellick Maneuver Evaluation in Rapid Sequence Induction of General Anesthesia Non Inferiority Trial	Completed	NCT02080754	Phase 3
35	Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial	Completed	NCT02031081	Phase 2, Phase 3	Prucalopride;Placebo
36	Magnetic Resonance (MR) Evaluation of the Effect of Erythromycin Upon Gastric and Small Bowel Motility	Completed	NCT01379183	Phase 2, Phase 3	Erythromycin;Placebo
37	A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy	Completed	NCT02250196	Phase 3	PEG-Asc;SPMC 2
38	Effects of the Abbreviation of Preoperative Fasting With Carbohydrates and Hydrolized Proteins on the Inflammatory Response and Insulin Resistance After Major Abdominal Operations	Completed	NCT01563965	Phase 3
39	Comparison of a Split Dose Bowel Preparation With 2-L Polyethylene Glycol Plus Ascorbic Acid and 1-L Polyethylene Glycol Plus Ascorbic Acid and Bisacodyl Prior to Colonoscopy	Completed	NCT02980562	Phase 3	Polyethylene Glycols;Bisacodyl
40	Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation	Completed	NCT03074448	Phase 3	Sodium Picosulfate
41	VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis	Recruiting	NCT04028492	Phase 3	Tradipitant;Placebo
42	Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy to Prevent Postoperative Pancreatic Fistula	Recruiting	NCT03419676	Phase 3
43	Treatment Protocol for the Compassionate Use of Domperidone	Recruiting	NCT01696734	Phase 3	Domperidone
44	Does the Strengthening of the Pancreas in Distal Pancreatectomy Using Endo GIA Reload Reinforced Reduce the Occurrence of Pancreatic Fistula? Multicenter Randomized Prospective Open Study	Recruiting	NCT03030170	Phase 3
45	A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis	Active, not recruiting	NCT03383146	Phase 3	Relamorelin;Placebo
46	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis	Active, not recruiting	NCT03426345	Phase 3	Relamorelin;Placebo
47	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis	Active, not recruiting	NCT03285308	Phase 3	Relamorelin;Placebo
48	Open-label Extension Study of Relamorelin for the Treatment of Diabetic Gastroparesis	Active, not recruiting	NCT03786380	Phase 3	Relamorelin 10 μg
49	A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis	Enrolling by invitation	NCT03420781	Phase 3	Relamorelin;Placebo
50	A Randomized, Placebo/Sham-Controlled, Double-Blind Crossover Study to Assess the Efficacy of Acupuncture in the Treatment of Diabetic Gastroparesis.	Suspended	NCT00470795	Phase 3

Search NIH Clinical Center for Gastroparesis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cisapride

Metoclopramide

Metoclopramide Hydrochloride

Cochrane evidence based reviews: gastroparesis

Sources

Genetic Tests for Gastroparesis

Sources

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

⁴⁰

Testes, Small Intestine, Lung, Colon, Bone, Smooth Muscle, Liver

Sources

Publications for Gastroparesis

Articles related to Gastroparesis:

(show top 50) (show all 2550)

#	Title	Authors	PMID	Year
1	Gastroparesis: Quality of Life and Health Care Utilization. ⁶¹ ⁵²	Lacy BE...Heinberg LJ	27775961	2018
2	Psychological controversies in gastroparesis: A systematic review. ⁵² ⁶¹	Woodhouse S...Knowles SR	28275310	2017
3	Gastroparesis: A Review of Current Diagnosis and Treatment Options. ⁶¹ ⁵²	Stein B...Lacy BE	25874755	2015
4	Gastroparesis: approach, diagnostic evaluation, and management. ⁶¹ ⁵²	Tang DM...Friedenberg FK	21329779	2011
5	Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. ⁶¹ ⁵⁴	Harsch IA...Konturek PC	19082715	2009
6	Postprandial secretion of ghrelin in hemodialysis patients with and without diabetic nephropathy. ⁵⁴ ⁶¹	Firczyk P...Wiecek A	19776684	2009
7	Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. ⁵⁴ ⁶¹	Camilleri M...Odunsi ST	19434096	2009
8	Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. ⁵⁴ ⁶¹	Ejskjaer N...Kosutic G	19298585	2009
9	Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. ⁵⁴ ⁶¹	Ang D...Tack J	19210631	2009
10	No ghrelin response to oral glucose in diabetes mellitus with gastroparesis. ⁶¹ ⁵⁴	Asai S...Tanaka Y	18946177	2009
11	Application of ghrelin to gastrointestinal diseases. ⁵⁴ ⁶¹	Venkova K...Greenwood-Van Meerveld B	18821473	2008
12	Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys. ⁵⁴ ⁶¹	Yogo K...Takanashi H	17934842	2008
13	Clinical trial: effect of mitemcinal (a motilin agonist) on gastric emptying in patients with gastroparesis - a randomized, multicentre, placebo-controlled study. ⁶¹ ⁵⁴	McCallum RW...Investigative Team	17894654	2007
14	Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders. ⁶¹ ⁵⁴	Peeters TL	17011824	2006
15	Ghrelin stimulates gastric emptying and hunger in normal-weight humans. ⁶¹ ⁵⁴	Levin F...Naslund E	16772353	2006
16	Abnormal ghrelin and pancreatic polypeptide responses in gastroparesis. ⁶¹ ⁵⁴	Gaddipati KV...Parkman HP	16868831	2006
17	Ghrelin gastrokinetic action in patients with neurogenic gastroparesis. ⁶¹ ⁵⁴	Binn M...Poitras P	16426704	2006
18	[The effects of enteral nutrition vs parenteral nutrition on gastric motility and gastroenteric hormones after subtotal gastrectomy: a perspective randomized compared clinical trial]. ⁵⁴ ⁶¹	Zhang Q...Qian JM	16836917	2006
19	Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. ⁶¹ ⁵⁴	Little TJ...Feinle-Bisset C	16492694	2006
20	Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. ⁵⁴ ⁶¹	Murray CD...Emmanuel AV	16085693	2005
21	Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. ⁶¹ ⁵⁴	Tack J...Peeters T	16225494	2005
22	Novel approaches to the treatment of nausea and vomiting. ⁶¹ ⁵⁴	Ladabaum U...Hasler WL	10697661	1999
23	Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. ⁵⁴ ⁶¹	Erbas T...Akalin S	8299441	1993
24	Erythromycin, motilin, and gastroparesis. ⁶¹ ⁵⁴	Yurkowski PJ...Calis KA	1464218	1992
25	Enhanced recovery outcomes following per-oral pyloromyotomy (POP): a comparison of safety and cost with same-day discharge versus inpatient recovery. ⁶¹	Landreneau JP...El-Hayek K	31482346	2020
26	Functional restoration of ex vivo model of pylorus: Co-injection of neural progenitor cells and interstitial cells of Cajal. ⁶¹	Dadhich P...Bitar KN	32181603	2020
27	Pathophysiology, Aetiology and Treatment of Gastroparesis. ⁶¹	Sullivan A...Ruban A	32350720	2020
28	Peroral Pyloromytomy is Effective and Safe for Postsurgical Gastroparesis. ⁶¹	Garg R...Sanaka MR	32166555	2020
29	Severe Gastroparesis After Ablation for Atrial Fibrillation. ⁶¹	Tanabe J...Tanabe K	32550092	2020
30	Pyloroplasty and the risk of Barrett's esophagus in patients with gastroparesis. ⁶¹	Alkhayyat M...Thota PN	32556104	2020
31	Temporary percutaneous radiologic gastrojejunostomy with single gastropexy. ⁶¹	Park JH...Ko HK	32517532	2020
32	Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. ⁶¹	Weusten BLAM...Martinek J	32375192	2020
33	Role of endoscopic functional luminal imaging probe in predicting the outcome of gastric peroral endoscopic pyloromyotomy (with video). ⁶¹	Vosoughi K...Khashab MA	32035074	2020
34	The High-Resolution Three-Dimensional Magnetic Detector System 3D-Magma Accurately Measures Gastric and Small Bowel Motility in People with Type 2 Diabetes with Neuropathy. ⁶¹	Jacob VYP...Stallmach A	32557505	2020
35	Gastrointestinal symptoms and cardiac vagal tone in type 1 diabetes correlates with gut transit times and motility index. ⁶¹	Wegeberg AL...Farmer AD	32573076	2020
36	FOXF2 acts as a crucial molecule in tumours and embryonic development. ⁶¹	He W...Guo W	32503970	2020
37	Proximal and Distal Gastric Retention Patterns in Gastroparesis and the Impact of Gastric Per-Oral Endoscopic Myotomy: A Retrospective Analysis Using Gastric Emptying Scintigraphy. ⁶¹	Spandorfer R...Cai Q	31811069	2020
38	Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data. ⁶¹	Camilleri M...Iacob A	32301137	2020
39	One-year results of per-oral pyloromyotomy for refractory gastroparesis: a multicenter study. ⁶¹	Ragi O...Gonzalez JM	32575130	2020
40	Impact of gastric per-oral endoscopic myotomy on static and dynamic pyloric function in gastroparesis patients. ⁶¹	Watts LS...Hasler WL	32542920	2020
41	Treating the pylorus in gastroparesis: The new riddle wrapped in the ultimate enigma? ⁶¹	Katzka DA...Camilleri M	32439098	2020
42	Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. ⁶¹	Ye Y...Ford AC	32493829	2020
43	Correction to: Pathophysiology of Gastroparesis Syndromes Includes Anatomic and Physiologic Abnormalities. ⁶¹	Abell TL...Pinkston C	32514641	2020
44	Gastric Peroral Endoscopic Myotomy (GPOEM): a Helpful Tool for Post Laparoscopic Sleeve Gastrectomy Gastroparesis. ⁶¹	Gonzalez JM...Vitton V	32524525	2020
45	Pyloric distensibility measurement after gastric surgery: Which surgeries are associated with pylorospasm? ⁶¹	Desprez C...Gourcerol G	31916346	2020
46	Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial. ⁶¹	Wegeberg AL...Brock C	32390563	2020
47	Therapies for diabetic gastroparesis: A protocol for a systematic review and network meta-analysis. ⁶¹	Wang S...Chen Q	32481350	2020
48	Reflux Symptoms in Gastroparesis: Correlation With Gastroparesis Symptoms, Gastric Emptying, and Esophageal Function Testing. ⁶¹	Jehangir A...Parkman HP	30762609	2020
49	Minimally invasive Roux-en-Y reconstruction as a salvage operation after failed nissen fundoplication. ⁶¹	Landreneau JP...El-Hayek K	31346753	2020
50	Atrial fibrillation ablation-induced gastroparesis: A case report and literature review. ⁶¹	Akhtar T...Spragg DD	32461887	2020

Sources

Genes for Gastroparesis

Genes related to Gastroparesis (0 elite genes):

(show all 24)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MLN	Motilin	Protein Coding	34.4	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)	17894654 11071469 17011824 (more) 17934842 1464218 9563538
2	MLNR	Motilin Receptor	Protein Coding	25.85	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	8299441 10697661
3	GAST	Gastrin	Protein Coding	25.11	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications Drugs & Compounds (show sections)	16836917
4	GHRL	Ghrelin And Obestatin Prepropeptide	Protein Coding	21.44	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16868831 16225494 19082715 (more) 18946177 18821473 16772353 19210631 19434096 16426704 19776684 19298585 17011824 16085693
5	GHSR	Growth Hormone Secretagogue Receptor	Protein Coding	20.98	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16225494 19298585 18946177
6	DRD2	Dopamine Receptor D2	Protein Coding	20.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Drugs & Compounds (show sections)
7	CYP2D6	Cytochrome P450 Family 2 Subfamily D Member 6	Protein Coding	19.11	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Drugs & Compounds (show sections)
8	CCK	Cholecystokinin	Protein Coding	19.01	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁴ GeneCards inferred via : Publications (show sections)	16836917
9	ABCB1	ATP Binding Cassette Subfamily B Member 1	Protein Coding	17.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Drugs & Compounds (show sections)
10	HTR3A	5-Hydroxytryptamine Receptor 3A	Protein Coding	13.3	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
11	NOS1	Nitric Oxide Synthase 1	Protein Coding	12.64	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
12	ANO1	Anoctamin 1	Protein Coding	12.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
13	HMOX1	Heme Oxygenase 1	Protein Coding	12.54	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
14	CYP3A4	Cytochrome P450 Family 3 Subfamily A Member 4	Protein Coding	12.2	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
15	SST	Somatostatin	Protein Coding	12.2	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
16	MRC1	Mannose Receptor C-Type 1	Protein Coding	12.2	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
17	GIP	Gastric Inhibitory Polypeptide	Protein Coding	12.1	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
18	DRD3	Dopamine Receptor D3	Protein Coding	11.96	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
19	TH	Tyrosine Hydroxylase	Protein Coding	11.94	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
20	DRD1	Dopamine Receptor D1	Protein Coding	11.78	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
21	KCNH2	Potassium Voltage-Gated Channel Subfamily H Member 2	Protein Coding	11.77	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	DRD5	Dopamine Receptor D5	Protein Coding	11.75	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
23	DRD4	Dopamine Receptor D4	Protein Coding	11.67	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)
24	PRL	Prolactin	Protein Coding	11.49	DISEASES inferred ¹⁵ GeneCards inferred via : Drugs & Compounds (show sections)

Sources

Variations for Gastroparesis

Sources

Expression for Gastroparesis

Search GEO for disease gene expression data for Gastroparesis.

Sources

Pathways for Gastroparesis

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 22)

#	Super pathways	Score	Top Affiliating Genes
1	Peptide ligand-binding receptors ⁶⁵ Show member pathways Class A/1 (Rhodopsin-like receptors) ⁶⁵ Defective AVP causes neurohypophyseal diabetes insipidus (NDI) ⁶⁵ Formyl peptide receptors bind formyl peptides and many other ligands ⁶⁵ G alpha (i) signalling events ⁶⁵ GPCR ligand binding ⁶⁵ GPCRs, Class A Rhodopsin-like ¹ Neuroactive ligand-receptor interaction ³⁶ Orexin and neuropeptides FF and QRFP bind to their respective receptors ⁶⁵ Peptide GPCRs ¹ Tachykinin receptors bind tachykinins ⁶⁵ Vasopressin-like receptors ⁶⁵	13.3	SST MLNR MLN GIP GHSR GHRL
2	Circadian entrainment ³⁶ Show member pathways Cholinergic synapse ³⁶ Dopaminergic synapse ³⁶ Glutamatergic synapse ³⁶ Synaptic Neurotransmission: Glutamatergic Excitation ⁶⁴	12.58	TH NOS1 DRD3 DRD2 DRD1
3	Dopamine-DARPP32 Feedback onto cAMP Pathway ⁶³	12.18	NOS1 DRD3 DRD2 DRD1
4	Circadian rythm related genes ¹	12.08	TH GHRL DRD3 DRD2 DRD1
5	cAMP signaling pathway ³⁶	11.97	SST GIP GHSR GHRL DRD2 DRD1
6	Monoamine GPCRs ¹ Show member pathways Adrenaline signalling through Alpha-2 adrenergic receptor ⁶⁵ Adrenoceptors ⁶⁵ Amine ligand-binding receptors ⁶⁵ Histamine receptors ⁶⁵ Muscarinic acetylcholine receptors ⁶⁵ Serotonin receptors ⁶⁵	11.82	DRD3 DRD2 DRD1
7	Imipramine/Desipramine Pathway, Pharmacokinetics ⁶⁰ Show member pathways Amitriptyline and Nortriptyline Pathway, Pharmacokinetics ⁶⁰ Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2 ⁶⁵ Candesartan Pathway, Pharmacokinetics ⁶⁰ Citalopram Pathway, Pharmacokinetics ⁶⁰ Clomipramine Pathway, Pharmacokinetics ⁶⁰ Clozapine Pathway, Pharmacokinetics ⁶⁰ Colchicine Metabolic Pathway ¹ Doxepin Pathway, Pharmacokinetics ⁶⁰ Lidocaine metabolism ¹ Metoprolol Pathway, Pharmacokinetics ⁶⁰ Nevirapine Pathway, Pharmacokinetics ⁶⁰ Olanzapine Pathway, Pharmacokinetics ⁶⁰ Paroxetine Pathway, Pharmacokinetics ⁶⁰ Proton Pump Inhibitor Pathway, Pharmacokinetics ⁶⁰ Venlafaxine Pathway, Pharmacokinetics ⁶⁰ Verapamil Pathway, Pharmacokinetics ⁶⁰ Warfarin Pathway, Pharmacokinetics ⁶⁰	11.78	CYP3A4 CYP2D6 ABCB1
8	Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics ⁶⁰ Show member pathways Nicotine Activity on Dopaminergic Neurons ¹ SNARE interactions in vesicular transport ³⁶	11.74	TH DRD3 DRD2
9	Carvedilol Pathway, Pharmacokinetics ⁶⁰ Show member pathways Clopidogrel Pathway, Pharmacokinetics ⁶⁰ Codeine and Morphine Metabolism ¹ Codeine and Morphine Pathway, Pharmacokinetics ⁶⁰ Ivacaftor pathway, pharmacokinetics/pharmacodynamics ⁶⁰ Losartan Pathway, Pharmacokinetics ⁶⁰ Macrolide Antibiotic Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Oxycodone Pathway, Pharmacokinetics ⁶⁰ Tacrolimus/Cyclosporine Pathway, Pharmacokinetics ⁶⁰ Tramadol Pharmacokinetics ⁶⁰	11.59	CYP3A4 CYP2D6 ABCB1
10	Phenytoin Pathway, Pharmacokinetics ⁶⁰ Show member pathways Atomoxetine Pathway, Pharmacokinetics ⁶⁰ Carbamazepine Pathway, Pharmacokinetics ⁶⁰ Cyclophosphamide Pathway, Pharmacokinetics ⁶⁰ Efavirenz Pathway, Pharmacokinetics ⁶⁰ Sorafenib Pharmacokinetics ⁶⁰	11.48	CYP3A4 CYP2D6 ABCB1
11	Ponatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Show member pathways Bosutinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Imatinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Nilotinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Taxane Pathway, Pharmacokinetics ⁶⁰	11.35	CYP3A4 CYP2D6 ABCB1
12	Erlotinib Pathway, Pharmacokinetics ⁶⁰ Show member pathways Atazanavir Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Dasatinib Pathway, Pharmacokinetics ⁶⁰ Gefitinib Pathway, Pharmacokinetics ⁶⁰	11.15	CYP3A4 CYP2D6 ABCB1
13	Pazopanib Pathway, Pharmacokinetics ⁶⁰ Show member pathways Sunitinib Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	11.11	CYP3A4 CYP2D6 ABCB1
14	Drug Induction of Bile Acid Pathway ¹	10.84	CYP3A4 ABCB1
15	Sirolimus Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.76	CYP3A4 ABCB1
16	Lamotrigine Pathway, Pharmacokinetics and Pharmacodynamics ⁶⁰	10.75	CYP2D6 ABCB1
17	Etoposide Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.74	CYP3A4 ABCB1
18	Ondansetron Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Show member pathways Tropisetron Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰	10.64	HTR3A CYP3A4 CYP2D6
19	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁵	10.62	TH DRD3 DRD2 DRD1
20	Vinka Alkaloid Pathway, Pharmacokinetics ⁶⁰	10.55	CYP3A4 ABCB1
21	Gastric acid production ¹	10.32	GAST CCK
22	Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics ⁶⁰	10.23	TH GHSR GHRL DRD2

Sources

GO Terms for Gastroparesis

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	synapse	GO:0045202	9.88	SST NOS1 HTR3A DRD3 DRD2 DRD1
2	neuronal cell body	GO:0043025	9.77	TH SST HTR3A GIP CCK
3	cell	GO:0005623	9.7	TH NOS1 HMOX1 GHRL DRD3 DRD2
4	axon	GO:0030424	9.65	TH HTR3A GHRL DRD2 CCK
5	GABA-ergic synapse	GO:0098982	9.61	DRD3 DRD2 DRD1
6	integral component of presynaptic membrane	GO:0099056	9.5	HTR3A DRD2 DRD1
7	dopaminergic synapse	GO:0098691	9.46	DRD3 DRD2
8	integral component of postsynaptic membrane	GO:0099055	9.13	HTR3A DRD2 DRD1
9	glutamatergic synapse	GO:0098978	9.1	HTR3A GHSR GHRL DRD3 DRD2 DRD1

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.27	MLNR HTR3A GIP GHSR GHRL GAST
2	cell-cell signaling	GO:0007267	10.03	SST DRD3 DRD2 DRD1
3	response to hypoxia	GO:0001666	9.98	TH NOS1 HMOX1 DRD2
4	response to ethanol	GO:0045471	9.9	TH HTR3A DRD3 DRD2
5	adenylate cyclase-modulating G protein-coupled receptor signaling pathway	GO:0007188	9.89	DRD3 DRD2 DRD1
6	cellular response to growth factor stimulus	GO:0071363	9.89	TH NOS1 HTR3A
7	response to nutrient levels	GO:0031667	9.88	TH GIP GHRL
8	learning	GO:0007612	9.88	TH DRD3 DRD1
9	excitatory postsynaptic potential	GO:0060079	9.87	HTR3A GHRL DRD2
10	response to hormone	GO:0009725	9.87	NOS1 GHSR GHRL
11	locomotory behavior	GO:0007626	9.86	TH DRD3 DRD2 DRD1
12	response to nicotine	GO:0035094	9.85	TH HMOX1 DRD2
13	memory	GO:0007613	9.84	TH GIP DRD1 CCK
14	positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway	GO:0051482	9.83	DRD3 DRD2 DRD1
15	positive regulation of multicellular organism growth	GO:0040018	9.83	GHSR GHRL DRD2
16	negative regulation of insulin secretion	GO:0046676	9.78	GHSR GHRL DRD2
17	negative regulation of blood pressure	GO:0045776	9.77	NOS1 DRD3 DRD2
18	negative regulation of tumor necrosis factor secretion	GO:1904468	9.75	GHSR GHRL
19	negative regulation of voltage-gated calcium channel activity	GO:1901386	9.75	DRD3 DRD2
20	exogenous drug catabolic process	GO:0042738	9.75	NOS1 CYP3A4 CYP2D6
21	oxidative demethylation	GO:0070989	9.74	CYP3A4 CYP2D6
22	negative regulation of synaptic transmission, glutamatergic	GO:0051967	9.74	DRD3 DRD2
23	behavioral response to ethanol	GO:0048149	9.74	DRD3 DRD2
24	neurotransmitter biosynthetic process	GO:0042136	9.74	TH NOS1
25	positive regulation of renal sodium excretion	GO:0035815	9.74	DRD3 DRD2
26	response to acidic pH	GO:0010447	9.74	SST GIP
27	grooming behavior	GO:0007625	9.74	DRD2 DRD1
28	G protein-coupled receptor internalization	GO:0002031	9.73	DRD3 DRD2
29	striatum development	GO:0021756	9.73	DRD2 DRD1
30	positive regulation of growth	GO:0045927	9.73	GHSR GHRL
31	adult feeding behavior	GO:0008343	9.73	GHSR GHRL
32	regulation of potassium ion transport	GO:0043266	9.73	DRD3 DRD2
33	visual learning	GO:0008542	9.73	DRD3 DRD2 DRD1 CCK
34	negative regulation of tumor necrosis factor biosynthetic process	GO:0042536	9.72	GHSR GHRL
35	adenylate cyclase-activating dopamine receptor signaling pathway	GO:0007191	9.72	DRD3 DRD1
36	positive regulation of growth hormone secretion	GO:0060124	9.72	GHRL DRD2
37	negative regulation of appetite	GO:0032099	9.72	GHSR CCK
38	peristalsis	GO:0030432	9.72	DRD2 DRD1
39	adenylate cyclase-activating adrenergic receptor signaling pathway	GO:0071880	9.72	DRD3 DRD2 DRD1
40	adenylate cyclase-inhibiting dopamine receptor signaling pathway	GO:0007195	9.71	DRD3 DRD2
41	hyaloid vascular plexus regression	GO:1990384	9.7	TH DRD2
42	mating behavior	GO:0007617	9.7	TH DRD1
43	heterocycle metabolic process	GO:0046483	9.7	CYP3A4 CYP2D6
44	dopamine receptor signaling pathway	GO:0007212	9.7	DRD3 DRD2 DRD1
45	response to drug	GO:0042493	9.7	TH SST GIP DRD3 DRD2 DRD1
46	drug catabolic process	GO:0042737	9.69	CYP3A4 CYP2D6
47	growth hormone secretion	GO:0030252	9.69	GHSR GHRL
48	behavioral response to cocaine	GO:0048148	9.69	DRD3 DRD2 DRD1
49	cerebral cortex GABAergic interneuron migration	GO:0021853	9.68	DRD2 DRD1
50	monoterpenoid metabolic process	GO:0016098	9.68	CYP3A4 CYP2D6

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	oxidoreductase activity	GO:0016491	9.89	TH NOS1 HMOX1 CYP3A4 CYP2D6
2	monooxygenase activity	GO:0004497	9.63	TH CYP3A4 CYP2D6
3	heme binding	GO:0020037	9.62	NOS1 HMOX1 CYP3A4 CYP2D6
4	drug binding	GO:0008144	9.61	DRD3 DRD2 CYP2D6
5	hormone binding	GO:0042562	9.48	MLNR GHSR
6	adrenergic receptor activity	GO:0004935	9.43	DRD3 DRD2 DRD1
7	hormone activity	GO:0005179	9.43	SST MLN GIP GHRL GAST CCK
8	dopamine neurotransmitter receptor activity, coupled via Gi/Go	GO:0001591	9.4	DRD3 DRD2
9	tetrahydrobiopterin binding	GO:0034617	9.37	TH NOS1
10	dopamine neurotransmitter receptor activity	GO:0004952	9.33	DRD3 DRD2 DRD1
11	dopamine binding	GO:0035240	8.92	TH DRD3 DRD2 DRD1

Sources

Sources for Gastroparesis

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Gastroparesis

Aliases & Classifications for Gastroparesis

MalaCards integrated aliases for Gastroparesis:

Classifications:

External Ids:

Summaries for Gastroparesis

Related Diseases for Gastroparesis

Diseases related to Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Gastroparesis:

Symptoms & Phenotypes for Gastroparesis

UMLS symptoms related to Gastroparesis:

GenomeRNAi Phenotypes related to Gastroparesis according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Gastroparesis:

Drugs & Therapeutics for Gastroparesis

Drugs for Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Cochrane evidence based reviews: gastroparesis

Genetic Tests for Gastroparesis

Anatomical Context for Gastroparesis

MalaCards organs/tissues related to Gastroparesis:

Publications for Gastroparesis

Articles related to Gastroparesis:

Genes for Gastroparesis

Genes related to Gastroparesis (0 elite genes):

Variations for Gastroparesis

Expression for Gastroparesis

Pathways for Gastroparesis

Pathways related to Gastroparesis according to GeneCards Suite gene sharing:

GO Terms for Gastroparesis

Cellular components related to Gastroparesis according to GeneCards Suite gene sharing:

Biological processes related to Gastroparesis according to GeneCards Suite gene sharing:

Molecular functions related to Gastroparesis according to GeneCards Suite gene sharing:

Sources for Gastroparesis

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :